Erratum: Tissue factor and cancer stem cells: Is there a linkage? (Arteriosclerosis, Thrombosis, and Vascular Biology (2010) 29 (2005-2014) DOI: 10.1161/ATVBAHA.108.177444));Tissue factor and cancer stem cells: Is there a linkage?

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 29, Issue 12, 2009, Pages 2005-2014

  Milsom, Chloe ^b,c   Magnus, Nathalie ^a   Meehan, Brian ^a   Al Nedawi, Khalid ^a   Garnier, Delphine ^a   Rak, Janusz ^b  

^a MONTREAL CHILDREN S HOSPITAL   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Angiogenesis; Cancer coagulopathy; Oncogenes; Tissue factor; Trousseau syndrome; Tumor initiating cells

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7A; CD133 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; KRUPPEL LIKE FACTOR 5; LEUKEMIA INHIBITORY FACTOR; OCTAMER TRANSCRIPTION FACTOR 4; PROCOAGULANT; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 2; PROTHROMBIN A; THROMBOPLASTIN; TRANSCRIPTION FACTOR NANOG; VIMENTIN;

CANCER GROWTH; CANCER STEM CELL; CELL COMPARTMENTALIZATION; CELL HETEROGENEITY; CLONAL VARIATION; EXTRACELLULAR MATRIX; FIBRIN DEPOSITION; HEMOSTASIS; METASTASIS; MICROENVIRONMENT; NONHUMAN; PRIORITY JOURNAL; REVIEW; THROMBOCYTE ACTIVATION; THROMBOSIS; TUMOR CELL; TUMOR GROWTH; TUMOR RECURRENCE; TUMOR VASCULARIZATION;

EID: 73849088329     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATV.0b013e3181fe3e1a     Document Type: Erratum

References (96)

1. Buller HR, van Doormaal FF, van Sluis GL, Kamphuisen PW. Cancer and thrombosis: from molecular mechanisms to clinical presentations. J Thromb Haemost. 2007;5:246-254.
2. Zwicker JI, Furie BC, Furie B. Cancer-associated thrombosis. Crit Rev Oncol Hematol. 2007;62:126-136.
3. Falanga A. Thrombophilia in cancer. Semin Thromb Hemost. 2005;31: 104-110.
4. Rickles FR. Mechanisms of cancer-induced thrombosis in cancer. Patho-physiol Haemost Thromb. 2006;35:103-110.
5. Varki A. Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood. 2007;110:1723-1729.
6. Rak J, Milsom C, Yu J. Tissue factor in cancer. Curr Opin Hematol. 2008;15:522-528.
7. Mackman N, Morrissey JH, Fowler B, Edgington TS. Complete sequence of the human tissue factor gene, a highly regulated cellular receptor that initiates the coagulation protease cascade. Biochemistry. 1989;28: 1755-1762.
8. Chen J, Bierhaus A, Schiekofer S, et al. Tissue factor-a receptor involved in the control of cellular properties, including angiogenesis. Thromb Haemost. 2001;86:334-345.
9. Fernandez PM, Rickles FR. Tissue factor and angiogenesis in cancer. Curr Opin Hematol. 2002;9:401-406.
10. Morrissey JH. Tissue factor: an enzyme cofactor and a true receptor. Thromb Haemost. 2001;86:66-74.
11. Giesen PL, Rauch U, Bohrmann B, et al. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci U S A. 1999;96:2311-2315.
12. Colman RW, Marder VJ, Salzman EW, Hirsh J. Overview of Hemostasis. In: Coleman RB, Hirsh J, Marder VJ, Salzman JB, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia: Lip-pincott Company; 1994:3-18.
13. Coughlin SR. Protease-activated receptors in vascular biology. Thromb Haemost. 2001;86:298-307.
14. Ruf W. Redundant signaling of tissue factor and thrombin in cancer progression? J Thromb Haemost. 2007;5:1584-1587.
15. Mackman N. Triggers, targets and treatments for thrombosis. Nature. 2008;451:914-918.
16. Albrektsen T, Sorensen BB, Hjorto GM, Fleckner J, Rao LV, Petersen LC. Transcriptional program induced by factor VIIa-tissue factor, PAR1 and PAR2 in MDA-MB-231 cells. J Thromb Haemost. 2007;5:1588-1597.
17. Rao LV, Pendurthi UR. Tissue factor-factor VIIa signaling. Arterioscler Thromb Vasc Biol. 2005;25:47-56.
18. Khorana AA, Ahrendt SA, Ryan CK, Francis CW, Hruban RH, Hu YC, Hostetter G, Harvey J, Taubman MB. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res. 2007;13:2870-2875.
19. Khorana AA, Francis CW, Menzies KE, Wang JG, Hyrien O, Hathcock J, Mackman N, Taubman MB. Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost. 2008; 6:1983-1985.
20. Kakkar AK, DeRuvo N, Chinswangwatanakul V, Tebbutt S, Williamson RC. Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor. Lancet. 1995;346:1004-1005.
21. Fotopoulou C, duBois A, Karavas AN, Trappe R, Aminossadati B, Schmalfeldt B, Pfisterer J, Sehouli J; Arbeitsgemeinschaft Gynaekolo-gische Onkologie Ovarian Cancer Study Group. Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum/ paclitaxel-containing first-line chemotherapy: an exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. J Clin Oncol. 2008;26:2683-2689.
22. Contrino J, Hair G, Kreutzer DL, Rickles FR. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phe-notype of human breast disease. Nat Med. 1996;2:209-215.
23. Zhang Y, Deng Y, Luther T, Müller M, Ziegler R, Waldherr R, Stern DM, Nawroth PP. Tissue factor controls the balance of angiogenic and anti-angiogenic properties of tumor cells in mice. J Clin Invest. 1994;94: 1320-1327.
24. Yu JL, May L, Lhotak V, Shahrzad S, Shirasawa S, Weitz JI, Coomber BL, Mackman N, Rak JW. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood. 2005;105:1734-1741.
25. Yu J, May L, Milsom C, Anderson GM, Weitz JI, Luyendyk JP, Broze G, Mackman N, Rak J. Contribution of host-derived tissue factor to tumor neovascularization. Arterioscler Thromb Vasc Biol. 2008;28:1975-1981.
26. Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, Hu Z, Barney KA, Degen JL. Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms. Blood. 2007;110:133-141.
27. Francis JL, Amirkhosravi A. Effect of antihemostatic agents on experimental tumor dissemination. Semin Thromb Hemost. 2002;28:29-38.
28. Yu JL, Rak JW. Shedding of tissue factor (TF)-containing microparticles rather than alternatively spliced TF is the main source of TF activity released from human cancer cells. J Thromb Haemost. 2004;2:2065-2067.
29. Milsom CC, Yu JL, Mackman N, Micallef J, Anderson GM, Guha A, Rak JW. Tissue factor regulation by epidermal growth factor receptor and epithelial-to-mesenchymal transitions: effect on tumor initiation and angiogenesis. Cancer Res. 2008;68:10068-10076.
30. Tesselaar ME, Romijn FP, van der Linden IK, Bertina RM, Osanto S. Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost. 2007;5:520-527.
31. Rauch U, Antoniak S. Tissue factor-positive microparticles in blood associated with coagulopathy in cancer. Thromb Haemost. 2007;97:9-10.
32. Del Conde I, Bharwani LD, Dietzen DJ, Pendurthi U, Thiagarajan P, López JA. Microvesicle-associated tissue factor and Trousseau's syndrome. J Thromb Haemost. 2007;5:70-74.
33. Yu JL, May L, Klement P, Weitz JI, Rak J. Oncogenes as regulators of tissue factor expression in cancer: implications for tumor angiogenesis and anti-cancer therapy. Semin Thromb Hemost. 2004;30:21-30.
34. Rong Y, Belozerov VE, Tucker-Burden C, et al. Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity. Cancer Res. 2009;69:2540-2549.
35. Al-Nedawi K, Meehan B, Micallef J, Lhotak V, May L, Guha A, Rak J. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol. 2008;10:619-624.
36. Al-Nedawi K, Meehan B, Kerbel RS, Allison AC, Rak J. Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR. Proc Natl Acad Sci U S A. 2009;106:3794-3799.
37. Ngo CV, Manning CA, McCabe F, et al. Combination antibody therapy targeting both xenograft-and host-derived tissue factor leads to potent tumor inhibition. Proc Am Assoc Cancer Res. 2005;46. Abstract.
38. Parry GC, Erlich JH, Carmeliet P, Luther T, Mackman N. Low levels of tissue factor are compatible with development and hemostasis in mice. J Clin Invest. 1998;101:560-569.
39. Carmeliet P, Mackman N, Moons L, Luther T, Gressens P, Van Vlaenderen I, Demunck H, Kasper M, Breier G, Evrard P, Müller M, Risau W, Edgington T, Collen D. Role of tissue factor in embryonic blood vessel development. Nature. 1996;383:73-75. (Pubitemid 26296462)
40. Cohen BD, Baker DA, Soderstrom C, Tkalcevic G, Rossi AM, Miller PE, Tengowski MW, Wang F, Gualberto A, Beebe JS, Moyer JD. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res. 2005;11:2063-2073.
41. Heppner GH. Tumor heterogeneity. Cancer Res. 1989;44:2259-2265.
42. Dick JE. Stem cell concepts renew cancer research. Blood. 2008;112: 4793-4807.
43. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105-111.
44. Zhu L, Gibson P, Currle DS, Tong Y, Richardson RJ, Bayazitov IT, Poppleton H, Zakharenko S, Ellison DW, Gilbertson RJ. Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation. Nature. 2009;457:603-607.
45. Rak J. Is cancer stem cell a cell, or a multicellular unit capable of inducing angiogenesis? Med Hypotheses. 2006;66:601-604.
46. Covello KL, Kehler J, Yu H, Gordan JD, Arsham AM, Hu CJ, Labosky PA, Simon MC, Keith B. HIF-2alpha regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev. 2006;20:557-570.
47. Jaenisch R, Young R. Stem cells, the molecular circuitry of pluripotency and nuclear reprogramming. Cell. 2008;132:567-582.
48. Dirks PB. Brain tumor stem cells: bringing order to the chaos of brain cancer. J Clin Oncol. 2008;26:2916-2924.
49. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133:704-715.
50. Thiery JP. Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol. 2003;15:740-746.
51. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008;8:755-768.
52. Al-Hajj M, Wicha MS, ito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100:3983-3988. (Pubitemid 36418143)
53. Gilbertson RJ, Rich JN. Making a tumour's bed: glioblastoma stem cells and the vascular niche. Nat Rev Cancer. 2007;7:733-736.
54. Calabrese C, Poppleton H, Hogg TL, Fuller C, Hamner B, Oh EY, Gaber MW, Finklestein D, Allen M, Frank A, Bayazitov IT, Zakharenko SS, Gajjar A, Davidoff A, Gilbertson RJ. A perivascular niche for brain tumor stem cells. Cancer Cell. 2007;11:69-82.
55. Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, Hjelmeland AB, Shi Q, McLendon RE, Bigner DD, Rich JN. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res. 2006;66:7843-7848.
56. Folkins C, Man S, Xu P, Shaked Y, Hicklin DJ, Kerbel RS. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res. 2007;67:3560-3564.
57. Rak J, Klement G. Impact of oncogenes and tumor suppressor genes on deregulation of hemostasis and angiogenesis in cancer. Cancer Metastasis Rev. 2000;19:93-96.
58. Milsom C, Anderson GM, Weitz JI, Rak J. Elevated tissue factor proco-agulant activity in CD133-positive cancer cells. J Thromb Haemost. 2007;5:2550-2552.
59. Versteeg HH, Schaffner F, Kerver M, Petersen HH, Ahamed J, Felding-Habermann B, Takada Y, Mueller BM, Ruf W. Inhibition of tissue factor signaling suppresses tumor growth. Blood. 2008;111:190-199.
60. Nierodzik ML, Karpatkin S. Thrombin induces tumor growth, metastasis, and angiogenesis: Evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell. 2006;10:355-362.
61. Morris DR, Ding Y, Ricks TK, Gullapalli A, Wolfe BL, Trejo J. Protease-activated receptor-2 is essential for factor VIIa and Xa-induced signaling, migration, and invasion of breast cancer cells. Cancer Res. 2006;66:307-314.
62. Belting M, Dorrell MI, Sandgren S, Aguilar E, Ahamed J, Dorfleutner A, Carmeliet P, Mueller BM, Friedlander M, Ruf W. Regulation of angio-genesis by tissue factor cytoplasmic domain signaling. Nat Med. 2004; 10:502-509.
63. Mueller BM, Reisfeld RA, Edgington TS, Ruf W. Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci U S A. 1992;89:11832-11836.
64. Dvorak FH, Rickles FR. Malignancy and Hemostasis. In: Coleman RB, Marder VJ, Clowes AW, George JN, Goldhaber SZ, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia: Lip-pincott Company Williams & Wilkins; 2006:851-873.
65. Toomey JR, Kratzer KE, Lasky NM, Broze GJ Jr. Effect of tissue factor deficiency on mouse and tumor development. Proc Natl Acad Sci U S A. 1997;94:6922-6926.
66. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759-767.
67. Dick JE. Looking ahead in cancer stem cell research. Nat Biotechnol. 2009;27:44-46.
68. Rak J, Klement P, Yu J. Genetic determinants of cancer coagulopathy, angiogenesis and disease progression. Vnitr Lek. 2006;52:135-138.:135-138.
69. Viloria-Petit AM, Rak J, Hung M-C, et al. Neutralizing antibodies against EGF and ErbB-2/neu receptor tyrosine kinases down-regulate VEGF production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol. 1997;151:1523-1530.
70. Bidlingmaier S, Zhu X, Liu B. The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells. J Mol Med. 2008; 86:1025-1032.
71. Hide T, Takezaki T, Nakamura H, Kuratsu J, Kondo T. Brain tumor stem cells as research and treatment targets. Brain Tumor Pathol. 2008;25:67-72.
72. Fidler IJ. The pathogenesis of cancer metastasis: the'seed and soil' hypothesis revisited. Nat Rev Cancer. 2003;3:453-458.
73. Hembrough TA, Swartz GM, Papathanassiu A, Vlasuk GP, Rote WE, Green SJ, Pribluda VS. Tissue factor/factor VIIa inhibitors block angio-genesis and tumor growth through a nonhemostatic mechanism. Cancer Res. 2003;63:2997-3000.
74. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature. 2000;407:258-264.
75. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100: 57-70.
76. Piccirillo SG, Combi R, Cajola L, Patrizi A, Redaelli S, Bentivegna A, Baronchelli S, Maira G, Pollo B, Mangiola A, DiMeco F, Dalprà L, Vescovi AL. Distinct pools of cancer stem-like cells coexist within human glioblastomas and display different tumorigenicity and independent genomic evolution. Oncogene. 2009;28:1807-1811.
77. Zacharski LR. Malignancy as a solid-phase coagulopathy: implications for the etiology, pathogenesis, and treatment of cancer. Semin Thromb Hemost. 2003;29:239-246.
78. Petralia GA, Lemoine NR, Kakkar AK. Mechanisms of disease: the impact of antithrombotic therapy in cancer patients. Nat Clin Pract Oncol. 2005;2:356-363.
79. Lee AY, Rickles FR, Julian JA, Gent M, Baker RI, Bowden C, Kakkar AK, Prins M, Levine MN. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol. 2005;23:2123-2129.
80. Tallman MS, Lefebvre P, Baine RM, Shoji M, Cohen I, Green D, Kwaan HC, Paietta E, Rickles FR. Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia. J Thromb Haemost. 2004;2:1341-1350.
81. Boccaccio C, Sabatino G, Medico E, Girolami F, Follenzi A, Reato G, Sottile A, Naldini L, Comoglio PM. The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature. 2005;434:396-400.
82. Rong Y, Post DE, Pieper RO, Durden DL, Van Meir EG, Brat DJ. PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res. 2005;65:1406-1413.
83. Liu TM, Wu YN, Guo XM, et al. Effects of ectopic nanog and oct4 overexpression on mesenchymal stem cells. Stem Cells Dev. In press.
84. Parisi S, Passaro F, Aloia L, Manabe I, Nagai R, Pastore L, Russo T. Klf5 is involved in self-renewal of mouse embryonic stem cells. J Cell Sci. 2008;121:2629-2634.
85. Ema M, Mori D, Niwa H, Hasegawa Y, Yamanaka Y, Hitoshi S, Mimura J, Kawabe Y, Hosoya T, Morita M, Shimosato D, Uchida K, Suzuki N, Yanagisawa J, Sogawa K, Rossant J, Yamamoto M, Takahashi S, Fujii-Kuriyama Y. Kruppel-like factor 5 is essential for blastocyst development and the normal self-renewal of mouse ESCs. Cell Stem Cell. 2008;3: 555-567.
86. Jiang J, Chan YS, Loh YH, Cai J, Tong GQ, Lim CA, Robson P, Zhong S, Ng HH. A core Klf circuitry regulates self-renewal of embryonic stem cells. Nat Cell Biol. 2008;10:353-360.
87. Camerer E, Gjernes E, Wiiger M, Pringle S, Prydz H. Binding of factor VIIa to tissue factor on keratinocytes induces gene expression. J Biol Chem. 2000;275:6580-6585.
88. Davey RE, Onishi K, Mahdavi A, Zandstra PW. LIF-mediated control of embryonic stem cell self-renewal emerges due to an autoregulatory loop. FASEB J. 2007;21:2020-2032.
89. Bauer S, Patterson PH. Leukemia inhibitory factor promotes neural stem cell self-renewal in the adult brain. J Neurosci. 2006;26:12089-12099.
90. Theodorou E, Dalembert G, Heffelfinger C, White E, Weissman S, Corcoran L, Snyder M. A high throughput embryonic stem cell screen identifies Oct-2 as a bifunctional regulator of neuronal differentiation. Genes Dev. 2009;23:575-588.
91. Petersen LC. Microarray studies of factor VIIa-activated cancer cells. Thromb Res. 2008;122:S11-S13.
92. Si W, Kang Q, Luu HH, Park JK, Luo Q, Song WX, Jiang W, Luo X, Li X, Yin H, Montag AG, Haydon RC, He TC. CCN1/Cyr61 is regulated by the canonical Wnt signal and plays an important role in Wnt3A-induced osteoblast differentiation of mesenchymal stem cells. Mol Cell Biol. 2006;26:2955-2964.
93. Luo Q, Kang Q, Si W, Jiang W, Park JK, Peng Y, Li X, Luu HH, Luo J, Montag AG, Haydon RC, He TC. Connective tissue growth factor (CTGF) is regulated by Wnt and bone morphogenetic proteins signaling in osteoblast differentiation of mesenchymal stem cells. J Biol Chem. 2004;279:55958-55968.
94. Pendurthi UR, Allen KE, Ezban M, Rao LV. Factor VIIa and thrombin induce the expression of Cyr61 and connective tissue growth factor, extracellular matrix signaling proteins that could act as possible downstream mediators in factor VIIa x tissue factor-induced signal transduction. J Biol Chem. 2000;275:14632-14641.
95. Wang X, Wang M, Amarzguioui M, Liu F, Fodstad Ø, Prydz H. Down-regulation of tissue factor by RNA interference in human melanoma LOX-L cells reduces pulmonary metastasis in nude mice. Int J Cancer. 2004;20:112:994-1002.
96. Provencal M, Labbé D, Veitch R, Boivin D, Rivard GE, Sartelet H, Robitaille Y, Gingras D, Béliveau R. c-Met activation in medullo-blastoma induces tissue factor expression and activity: effects on cell migration. Carcinogenesis. 2009:30;1089-1096.